INTELLIGENT BIO SOLUTIONS IN (INBS) Stock News
NASDAQ:INBS - Nasdaq - US36151G6008 - Common Stock - Currency: USD
INBS Latest News, Press Relases and Analysis
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Stay updated with the stocks that are on the move in today's pre-market session.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares of Common Stock
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering...
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering...
Which stocks are moving after the closing bell on Wednesday?
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering...
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track...
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025...
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in...
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 ...
EXCLUSIVE: Intelligent Bio Solutions Expects To Record Increased Profitability In Q2 On Higher-Margin Sales
Intelligent Bio Solutions reports rising sales and profit margins, driven by recurring revenue from cartridge sales and global expansion through key partnerships.
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia...
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening Most recent client...
EXCLUSIVE: Intelligent Bio Solutions Partners With UK-Based Quantum TM For Fingerprint Drug Testing At 10 Sites
Quantum Traffic Management adopts INBS' Intelligent Fingerprinting Drug Testing Solution to improve efficiency and safety, with plans to expand in US.
Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
Princebuild has moved from saliva testing to INBS' fingerprint drug testing solution to implement a more streamlined, in-house solution across seven...
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company...
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data...
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company...
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin,...
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program....
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue...
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
INBS announces one year of enhanced workplace safety with Mount Anvil following the integration of fingerprint drug testing. ...
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity...
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
INBS announces its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency....
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts. ...
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan. ...
UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company...
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights
- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024,...
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (